Journal
NEUROLOGY
Volume 78, Issue 17, Pages 1346-1353Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182535d0c
Keywords
-
Categories
Funding
- American Academy of Neurology
- American Headache Society
- Albert Einstein College of Medicine
- AGA
- Allergan
- Boston Scientific
- Capnia
- Coherex
- Endo Pharmaceuticals
- GlaxoSmithKline
- Lilly
- MAP
- Medtronic
- Merck
- NINDS
- NuPathe
- St. Jude Medical
- Valeant Pharmaceuticals
- Advanced Neurostimulation Systems
- St Jude Medical, Inc.
- NINDS/NIH
- Mayo Clinic
- Forest Laboratories
- Eli Lilly
- Neurogesx
- Pfizer
- NIH
Ask authors/readers for more resources
Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs) or other complementary treatments effective for migraine prevention? Methods: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications for migraine prevention. Results: The author panel reviewed 284 abstracts, which ultimately yielded 49 Class I or Class II articles on migraine prevention; of these 49, 15 were classified as involving nontraditional therapies, NSAIDs, and other complementary therapies that are reviewed herein. Recommendations: Petasites (butterbur) is effective for migraine prevention and should be offered to patients with migraine to reduce the frequency and severity of migraine attacks (Level A). Fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew), magnesium, riboflavin, and subcutaneous histamine are probably effective for migraine prevention (Level B). Treatments considered possibly effective are cyproheptadine, Co-Q10, estrogen, mefenamic acid, and flurbiprofen (Level C). Data are conflicting or inadequate to support or refute use of aspirin, indomethacin, omega-3, or hyperbaric oxygen for migraine prevention. Montelukast is established as probably ineffective for migraine prevention (Level B). Neurology (R) 2012; 78: 1346-1353
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available